CHCWM – Cancer & Hematology Centers of West Michigan

Cardiff Oncology CRDF-01E (EAP)

An Expanded Access Program of Onvansertib in Combination with FOLFIRI and Bevacizumab for the Second-Line Treatment of Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

MERCK (KeyVibe-008)

  A Phase 3, Randomized, Double-Blind Study of MK-7684A in Combination with Etoposide and Platinum Followed by MK-7684A vs Atezolizumab in Combination with Etoposide and Platinum Followed by Atezolizumab for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer PI: Dr. Chen Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center

Merck MK-7339-003 (LYNK-003)

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003) Principal Investigator: Dr. Sreenivasa Chandana For more information on this

Merck MK7902-015 (LEAP015)

  A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Lenvatinib (E7080/MK 7902) plus Pembrolizumab (MK-3475) plus Chemotherapy Compared with Standard of Care Therapy as First-line Intervention in Participants with Advanced/Metastatic Gastroesophageal Adenocarcinoma (LEAP-015) PI: Dr. Chandana Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton

MERCK MK7864A-007

  A Randomized, Double-Blind, Phase 3 Study of MK-7684A Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy as First Line Treatment for Participants With Metastatic Non-Small Cell Lung Cancer PI: Dr Chen Available at: CHCWM – Muskegon, Holland Cancer Center, Lacks Cancer Center at Saint Mary’s, Lemmen-Holton Cancer Pavilion

PAL-E602-001 (Palleon)

Description:  A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination with Pembrolizumab in Patients with Advanced Cancers Mechanism of Action:  cleaves off immunosuppressive sialoglycans from immune and tumor cells to enhance antitumor immunity Target Patient Population:   Melanoma,

SY-5609-101 (Syros)

SY-5609-101 (Syros) Description:  A Phase 1 Study of SY-5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients with Select Advanced Solid Tumors Mechanism of Action:  CDK7 inhibitor Target Patient Population:   Metastatic breast cancer, ovarian, lung, colorectal or any malignancy with mutation of RB1, CDKN1A/CDKN2A, amplification of CCNE1, CCND1, CCND2, CDK4 or CDK6); in combination with

Sym024-01 (Symphogen)

Description: A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym024 (Anti-CD73) as Monotherapy and in Combination with Sym021 (Anti-PD-1) in Patients with Advanced Solid Tumor Malignancies Mechanism of Action:  Anti-CD73 (Sym024) with or without Anti-PD-1 (Sym021).  CD73 is cell surface bound enzyme which converts AMP to adenosine.  In tumor

TH1902-CTR-0001 (Theratechnologies, Inc.)

Description:  A Phase 1, Open-Label, Dose Escalation Study of TH1902 in Patients with Advanced Solid Tumors and Expansion in Patients with Triple Negative Breast Cancer (TNBC), Gynecological Cancer, Colorectal Cancer and Pancreatic Cancer Mechanism of Action:  Peptide-drug conjugate that binds to SORT-1 with a docetaxel payload. Target Patient Population:  Currently in Dose Escalation with all